Bavarian Nordic A/S (OTCMKTS:BVNRY) Releases Earnings Results, Beats Expectations By $0.07 EPS

Bavarian Nordic A/S (OTCMKTS:BVNRY) released its quarterly earnings results on Wednesday. The company reported $0.47 EPS for the quarter, topping the consensus estimate of $0.40 by $0.07, Zacks reports. Bavarian Nordic A/S had a return on equity of 10.65% and a net margin of 18.33%.

Bavarian Nordic A/S Stock Up 4.7 %

Bavarian Nordic A/S stock opened at $8.04 on Thursday. The firm has a 50-day moving average price of $8.55 and a two-hundred day moving average price of $9.91. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of 11.65 and a beta of 1.68. Bavarian Nordic A/S has a 52-week low of $6.86 and a 52-week high of $14.60.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.